MTOR and breast carcinoma: However, a combination of endocrine therapy with other signaling pathways like PI3K/AKT/mTOR and Ras/Raf/MEK/ERK and coregulatory factors targeted agent should be the focus of future treatment, especially in endocrine-resistant breast cancer.